COVID-19 Press Briefing

April 2, 2021
The Vaccination Progress Report

7-day average daily doses administered by week as of 4/1/2021*

Doses per day

*7-day average from March 3 – March 9 was 2.2M
Daily Change in COVID-19 Cases, US
January 22, 2020 – March 31, 2021

TOTAL Cases Reported Since 1/22/20
30,277,908

NEW Cases Reported to CDC on 3/31/21
64,149

Change in 7-Day Case Average
+8.4%

Current 7-Day Case Average (3/25/21 - 3/31/21)
62,167

Prior 7-Day Case Average (3/18/21 - 3/24/21)
57,343

Reported 7-day moving average* of COVID-19 cases has decreased 75% since January 11, 2021

<table>
<thead>
<tr>
<th>Peaks in New Cases and Highest 7-Day Moving Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highest Daily Number of New Cases</td>
</tr>
<tr>
<td>Current</td>
</tr>
<tr>
<td>2nd Peak</td>
</tr>
<tr>
<td>1st Peak</td>
</tr>
</tbody>
</table>

*Reported 7-day moving average calculated as the average of the number of new cases reported over the last 7 days, weighted by the number of days since the cases were reported.
New Admissions of Patients with Confirmed COVID-19
August 1, 2020 – March 30, 2021

Patients Currently Hospitalized with COVID on 3/30/21
33,748

New Admissions on 3/30/21
5,261

Peak in New Admissions (1/5/21)
17,993

Change in 7-Day Average of New Admissions
+4.8%

Current 7-Day Average of New Admissions (3/24/21 - 3/30/21)
4,948

Prior 7-Day Average of New Admissions (3/17/21 - 3/23/21)
4,722

Reported 7-day moving average of hospitalizations has decreased 70% since January 9, 2021
Daily Change in COVID-19 Deaths, United States
January 22, 2020 – March 31, 2021

TOTAL Deaths Reported Since 1/22/2020
549,098

NEW Deaths Reported to CDC on 3/31/21
917

Change in 7-Day Death Average
-7.7%

Current 7-Day Death Average (3/25/21 - 3/31/21)
880

Prior 7-Day Death Average (3/18/21 - 3/24/21)
953

Forecasted Total Deaths by 4/24/21
565,000 to 585,000
WEAR A MASK

STAY 6 FEET APART

AVOID CROWDS

AVOID TRAVEL
COVID-19 Vaccine Update: More Positive News from “Real World” Studies and Clinical Trials

- MMWR: Messenger RNA (mRNA) COVID-19 vaccines 90% effective in real world conditions
- Pfizer reports vaccine 100% protective in adolescents
- Pfizer reports vaccine protection in adults up to 6 months
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

- Prospective study; n=3,950
- Participants self-collected nasal swabs each week for RT-PCR laboratory testing
- mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; 80% after one dose
- 3 PCR-confirmed infections occurred during 78,902 person-days with full immunization (0.04/1,000 person-days)
Pfizer and Biontech Confirm High Efficacy and No Serious Safety Concerns Through up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

- 91.3% efficacy against COVID-19, measured seven days through up to six months after the second dose
- ~95-100% efficacy against severe disease
- No safety concerns to date
- In South Africa (N=800), 6 cases of B.1.351 variant in placebo group and 0 in vaccinated group
Rationale for SARS-CoV-2 Trials in Pediatric and Adolescent Populations

- Goal: SARS-CoV-2 vaccine for entire U.S. population

- Children and adolescents make up 22% of the U.S. population*

- Emerging data suggests that vaccination prevents asymptomatic carriage, thus reversing pandemic more rapidly

*census.gov
News Release

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

- In participants aged 12-15 years, BNT162b2 was well-tolerated and demonstrated 100% efficacy (18 cases of COVID-19 in placebo group and 0 cases in vaccine group) and robust antibody responses; n=2,260

- Companies plan to submit data to FDA as soon as possible to request expansion of the Emergency Use Authorization (EUA) for the vaccine

- Study underway in children aged 6 months to 11 years
  - 5-to-11 year old cohort started dosing last week; 2-to-5 year old cohort to begin next week
COVID-19
Public Education Campaign
Goals

1. **Educate** on how to protect yourself & slow the spread of COVID-19
2. **Build trust** in vaccines with accurate information from trusted sources
3. **Increase awareness** about how to get vaccinated when ready
Role of trusted messengers

Trusted community members: essential for health education & empowerment

- Effectively deliver messages and strategies
- Validate the credibility of information
- Address mis- and disinformation
- Create a feedback loop for addressing questions and concerns
- Bridge the gap between healthcare providers and patients

Friends  Pharmacists  Nurses  Faith Community
COVID-19 Community Corps

- Galvanize trusted voices in communities
- Provide toolkits & resources to organize & educate
- Receive scientific updates, infographics, factsheets, & tools on ways to help people get registered and vaccinated
Join us online at

WeCanDoThis.hhs.gov